UNSPSC 51422213: Triamcinolone acetonide valerate

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H39FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H6942ZVG0C, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-21-((1-oxopentyl)oxy)-, (11.beta.,16.alpha.)-, but more generally known as triamcinolone acetonide valerate, which bears US NIH Compound Identifier 60904.

European Medicines Agency schedules triamcinolone acetonide valerate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG. Most nations, for tariff purposes, schedule triamcinolone acetonide valerate under HS 29372200. SMILES: CCCCC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC(O2)(C)C.

UNSPSC 51422213 Triamcinolone acetonide valerate is a Commodity code for a pharmaceutical active ingredient used in topical corticosteroid formulations. However, the recent state and local procurement activity indexed under this code does not reflect pharmaceutical manufacturing or supply; instead, a Seminole County, Florida IFB solicitation tags the code while procuring naloxone and drug deactivation systems for community health initiatives — a substantial mismatch between the code's nominal pharmaceutical scope and the actual goods being bought. The code shows minimal relevant recent activity in state and local markets.

Seminole County issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. The bid required unit pricing for each line item, e-Verify compliance, drug-free workplace certification, and standard insurance coverage (workers' compensation, commercial general liability, and professional liability). The contract carried a two-year initial term with a one-year renewal option and included a three-month probationary period. The opportunity noted potential FEMA funding and associated federal compliance obligations under the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations for disadvantaged enterprises were stated. This solicitation's tagging under a topical corticosteroid code suggests either a cataloging error by the county or a broad pharmaceutical-adjacent classification that does not serve as a reliable indicator of future opportunities in triamcinolone acetonide valerate supply.